An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Monthly information on share capital and company voting rights
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.
Positive
None.
Negative
None.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, May 06, 2024 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
Date
Total number of shares in the capital
Total number of voting rights
04/30/2024
71,955,535
77,891,229
For further information on Cellectis, please contact:
What is the total number of shares in the capital for Cellectis as of April 30, 2024?
The total number of shares in the capital for Cellectis as of April 30, 2024, was reported to be 71,955,535.
How many voting rights does Cellectis have as of April 30, 2024?
Cellectis had a total of 77,891,229 voting rights as of April 30, 2024.
What is the ISIN code for Cellectis?
The ISIN code for Cellectis is FR0010425595.
What is the date of the report on share capital and voting rights provided by Cellectis?
The report on share capital and voting rights was provided by Cellectis on April 30, 2024.
Who can be contacted for media inquiries regarding Cellectis?
For media inquiries regarding Cellectis, you can contact Pascalyne Wilson, Director of Communications, at +33 (0)7 76 99 14 33 or Patricia Sosa Navarro, Chief of Staff to the CEO, at +33 (0)7 76 77 46 93.
Who are the Investor Relations contacts for Cellectis?
The Investor Relations contacts for Cellectis are Arthur Stril, the Chief Financial Officer (interim), at +1 (347) 809 5980 and Ashley R. Robinson from LifeSci Advisors at +1 617 430 7577.
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
